Home Top Stories FIP urges greater pharmacists role in medicine selection

FIP urges greater pharmacists role in medicine selection

0
27

The International Pharmaceutical Federation (FIP) has called for pharmacists to be given greater responsibility in selecting medicines, including generic substitution and therapeutic interchange, to improve access to treatment and patient outcomes.

The call was made in a new policy statement released on 3 September 2026, as part of resolutions from the just concluded World Congress of the FIP, held  in Montreal, Canada, from 30 August to 2 September.

The policy replaces FIP’s 2018 policy on pharmacists’ authority in pharmaceutical product selection and reflects changes in healthcare, including the increasing use of generic and biosimilar medicines, digital health technologies and the growing challenge of medicine shortages.

According to the global body of pharmacists, pharmacists should be allowed, where national laws permit, to use their clinical knowledge to make evidence-based decisions on medicine selection.

The federation said this could help patients maintain continuity of care, improve access to medicines and support health systems facing financial and supply pressures.

“Pharmacists are the healthcare professionals with the greatest expertise in medicines, making them ideally placed to lead pharmaceutical product selection,” said Mr Daragh Connolly, co-chair of the policy committee.

He added that giving pharmacists the opportunity to practise according to their competence could benefit both patients and health systems as healthcare needs become more complex.

The policy also calls for patients to be involved when changes are made to their medicines.

Mr Lars-Åke Söderlund, another co-chair of the policy committee, said pharmacists should explain why a medicine is being substituted or changed and address concerns that could affect patients’ confidence in their treatment.

FIP also stressed the importance of collaboration between pharmacists, prescribers and other healthcare professionals to ensure that changes to medicines are safe and properly coordinated.

The policy further highlights the role of digital technology in medicine optimisation. It encourages the use of electronic health records, clinical decision-support systems and real-world evidence to improve patient safety, pharmacovigilance and continuity of care.

FIP noted that pharmacists can play an important role in responding to medicine shortages, strengthening medicine supply chains and supporting more sustainable healthcare.

The federation called on governments and policymakers to create clear legal frameworks that allow pharmacists to contribute fully to medicine selection. It also urged stakeholders to strengthen public understanding and confidence in generic and biosimilar medicines.

FIP further called for investment in pharmacists education, digital infrastructure and collaborative models of care to support better use of medicines.

The federation said strengthening pharmacist-led, evidence-based medicine selection could improve patient outcomes, expand access to treatment and help build more resilient healthcare systems worldwide.

LEAVE A REPLY

Please enter your comment!
Please enter your name here